股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 達芙妮國際控股有限公司 呈交日期: 2026年2月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00210 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 10,000,000,000 | HKD | | 0.1 HKD | | 1,000,000,000 | | 增加 / 減少 (-) | | | 0 | | | HKD | | 0 | | 本月底結存 | | | 10,000,000,000 | HKD | | 0.1 HKD | | 1,000,000,000 | 本月底法定/註冊股本總額： HKD ...

Core Viewpoint - Wohuah Pharmaceutical (002107.SZ) has reported a significant increase in net profit for 2025, achieving a 162.93% year-on-year growth, marking the highest increase in nearly a decade, amidst a challenging industry environment [1] Group 1: Financial Performance - In 2025, Wohuah Pharmaceutical achieved total operating revenue of 817 million yuan, representing a year-on-year growth of 6.96% [1] - The net profit attributable to shareholders reached 95.72 million yuan, reflecting a substantial increase of 162.93% [1] - The net cash flow from operating activities increased by 40.45% year-on-year, indicating strong cash generation capabilities [1] Group 2: Strategic Initiatives - The company has implemented a robust strategy focusing on its unique product line, particularly in the cardiovascular and chronic disease sectors [1] - Wohuah Pharmaceutical plans to optimize its production system in 2025, enhancing operational efficiency and supply chain resilience through resource collaboration and technological upgrades [2] - The company aims to deepen its focus on proprietary products and expand its market presence while maintaining a strong financial structure for potential capital operations [2] Group 3: Market Outlook - The Chinese traditional medicine market is expected to continue its rapid growth, supported by favorable policies and the introduction of new products [2] - The company is committed to refining its management practices to improve operational efficiency and shareholder returns [2]

Core Viewpoint - Wohuah Pharmaceutical (002107.SZ) has reported a significant increase in net profit for 2025, achieving a 162.93% year-on-year growth, marking the highest increase in nearly a decade, despite a challenging industry environment [2] Group 1: Financial Performance - In 2025, Wohuah Pharmaceutical achieved total revenue of 817 million yuan, representing a year-on-year growth of 6.96% [2] - The net profit attributable to shareholders reached 95.72 million yuan, reflecting a substantial increase of 162.93% [2] - The net cash flow from operating activities increased by 40.45% year-on-year, indicating strong cash generation capabilities [2] Group 2: Strategic Initiatives - The company has maintained a "strong exclusive product line" strategy, focusing on proprietary products in the cardiovascular and chronic disease sectors [2] - Wohuah Pharmaceutical plans to implement a strategic optimization and restructuring of its production system in 2025, aiming for efficient integration and cost reduction [3] - The company intends to deepen its focus on proprietary product lines and enhance clinical value and market synergy while responding to ongoing procurement policies [3] Group 3: Future Outlook - Wohuah Pharmaceutical aims to strengthen its research and access strategies, leveraging a solid financial structure for potential capital operations around its core business [3] - The company is expected to continue benefiting from favorable policies supporting the traditional Chinese medicine market, which is projected to maintain rapid growth [3]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 達芙妮國際控股有限公司 呈交日期: 2026年1月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00210 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 10,000,000,000 | HKD | | 0.1 HKD | | 1,000,000,000 | | 增加 / 減少 (-) | | | 0 | | | HKD | | 0 | | 本月底結存 | | | 10,000,000,000 | HKD | | 0.1 HKD | | 1,000,000,000 | 本月底法定/註冊股本總額： HK ...

Core Viewpoint - The control of Cangzhou Mingzhu (002108) is set to change, with Guangzhou Light Industry becoming the new controlling shareholder, and the actual controller will be the Guangzhou State-owned Assets Supervision and Administration Commission [1][2]. Group 1: Share Transfer Details - Guangzhou Light Industry will acquire 166,539,465 shares from Dongsu Group, representing 10.10% of the total share capital as of the agreement date [1]. - Dongsu Group and its concerted parties will delegate voting rights for an additional 159,609,160 shares (9.68% of total share capital) to Guangzhou Light Industry, giving it a total voting power of 19.78% in the company [1][2]. - As of the announcement date, Dongsu Group holds 313,912,903 shares (19.04% of total share capital) and is the current controlling shareholder [2]. Group 2: Company Background and Performance - Cangzhou Mingzhu was established in 1995 and operates six wholly-owned subsidiaries, two holding subsidiaries, two branches, and three associated companies, with major industrial parks in Cangzhou and production bases in Shandong, Anhui, and Chongqing [2]. - The company has faced performance pressure in recent years, with negative growth in net profit since the third quarter of 2023, although there was a slight increase of 0.99% in net profit year-on-year for the first three quarters, and revenue grew by 5.90% to 2.078 billion yuan [2][3]. - The sales revenue of PE pipe products has decreased compared to the previous year, while BOPA film products have seen an increase in both sales volume and revenue, with improved profitability [3]. Group 3: Market Reaction - Following the announcement, Cangzhou Mingzhu's stock opened nearly 4% higher on December 16 but later retreated, closing with a 1.29% increase at 4.72 yuan per share, giving it a market capitalization of 7.78 billion yuan [3].

该信息由智通财经网提供 智通财经APP讯，达芙妮国际(00210)发布公告，执行董事王俊刚先生，为了投放更多时间于彼之其他事 务，已调任为非执行董事并辞任公司营运总监，自2025年12月11日起生效。 ...

达芙妮国际(00210)发布公告，执行董事王俊刚先生，为了投放更多时间于彼之其他事务，已调任为非 执行董事并辞任公司营运总监，自2025年12月11日起生效。 ...

格隆汇12月11日丨达芙妮国际(00210.HK)公告，执行董事王俊刚，为了投放更多时间于彼其他事务，已 调任为非执行董事并辞任公司营运总监，自2025年12月11日起生效。 ...

DAPHNE INTERNATIONAL HOLDINGS LIMITED 達 芙 妮 國 際 控 股 有 限 公 司* ( 於開曼群島註冊成立之有限公司 ) (股份代號： 210) 董事名單與其角色和職能 達芙妮國際控股有限公司之董事會﹝「董事會」﹞成員載列如下： 執行董事： | 委員會 | 審核委員會 | 薪酬委員會 | 提名委員會 | | --- | --- | --- | --- | | 董事 | | | | | 張智凱先生 | - | M | M | | 張智喬先生 | - | - | - | | 張椀絢女士 | - | - | - | | 王俊剛先生 | - | - | - | | 韓炳祖先生 | C | M | M | | 談大成先生 | M | C | M | | 許文冠女士 | M | M | C | C – 有關委員會之主席 M – 有關委員會之成員 香港，二零二五年十二月十一日 * 僅供識別 張智凱先生 ﹝主席﹞ 張智喬先生 ﹝行政總裁﹞ 張椀絢女士 非執行董事： 王俊剛先生 獨立非執行董事： 韓炳祖先生 談大成先生 許文冠女士 董事會設立三個委員會。下表提供各董事會成員在該等委員會中所 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對 其準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部份 內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 DAPHNE INTERNATIONAL HOLDINGS LIMITED 達 芙 妮 國 際 控 股 有 限 公 司 * ( 於開曼群島註冊成立之有限公司 ) (股份代號： 210) 董事調任 達芙妮國際控股有限公司（「本公司」）董事會（「董事會」，各自為「董事」）謹 此宣佈，執行董事王俊剛先生（「王先生」），為了投放更多時間於彼之其他事務， 已調任為非執行董事並辭任本公司營運總監，自二零二五年十二月十一日起生效。 * 僅供識別 1 王先生已與本公司訂立服務合約及彼之三年任期內作為董事，惟須根據本公司之組織 章程細則於本公司舉行之股東週年大會輪席退任及重選，其每年酬金為人民幣 726,000 元（並無酌情花紅）。該酬金是由本公司薪酬委員會參考，其中包括，本公司之薪酬 政策及彼作為非執行董事的職責作出之考慮及建議而釐定。 除上述披露者外，截至本公告日期，王先生（i）並無於本公司或其之附屬公司擔任任 何其 ...